Menu Search
Equities

aTyr Pharma Inc

471A:BER

aTyr Pharma Inc

Actions
  • Price (EUR)1.67
  • Today's Change-0.01 / -0.60%
  • Shares traded--
  • 1 Year change+9.15%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 18:37 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year aTyr Pharma Inc's revenues fell -96.60% from 10.39m to 353.00k. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 45.34m to a larger loss of 50.39m.
Gross margin--
Net profit margin-9,846.26%
Operating margin-10,633.50%
Return on assets-48.51%
Return on equity-61.64%
Return on investment-53.89%
More ▼

Cash flow in USDView more

In 2023, aTyr Pharma Inc increased its cash reserves by 97.99%, or 12.88m. Cash Flow from Financing totalled 66.23m or 18,762.04% of revenues. In addition the company used 33.22m for operations while cash used for investing totalled 20.13m.
Cash flow per share-0.8951
Price/Cash flow per share--
Book value per share1.08
Tangible book value per share1.08
More ▼

Balance sheet in USDView more

aTyr Pharma Inc uses little debt in its capital structure as supported by a debt to capital ratio of 2.02%.
Current ratio7.63
Quick ratio--
Total debt/total equity0.0206
Total debt/total capital0.0202
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.